Antipsychotic drug trifluoperazine as a potential therapeutic agent against nasopharyngeal carcinoma

Background Trifluoperazine (TFP) is a typical antipsychotic primarily used to treat schizophrenia. In this study, we aimed to evaluate whether TFP can be used as a therapeutic agent against nasopharyngeal carcinoma (NPC) and identify its underlying molecular mechanisms. Methods We used NPC‐TW01, TW0...

Full description

Saved in:
Bibliographic Details
Published inHead & neck Vol. 45; no. 2; pp. 316 - 328
Main Authors Yeh, Chien‐Fu, Lee, Wen‐Ya, Yu, Ting‐Han, Hsu, Yen‐Bin, Lan, Ming‐Chin, Lan, Ming‐Ying
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.02.2023
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background Trifluoperazine (TFP) is a typical antipsychotic primarily used to treat schizophrenia. In this study, we aimed to evaluate whether TFP can be used as a therapeutic agent against nasopharyngeal carcinoma (NPC) and identify its underlying molecular mechanisms. Methods We used NPC‐TW01, TW03, TW04, and BM to assess the anticancer effects of TFP by using cytotoxicity, wound healing, colony formation, and cell invasion assays. An in vivo animal study was conducted. RNA sequencing combined with Ingenuity Pathways Analysis was performed to identify the mechanism by which TFP influences NPC cells. Results Our data revealed that TFP decreased NPC cell viability in a dose‐dependent manner. The invasion and migration of NPC tumor cells were inhibited by TFP. An in vivo study also demonstrated the anticancer effects of TFP. RNA sequencing revealed several anticancer molecular mechanisms following TFP administration. Conclusions The antipsychotic drug TFP could be a potential therapeutic regimen for NPC treatment.
Bibliography:Funding information
Ministry of Science and Technology, Taiwan, Grant/Award Number: MOST 110‐2628‐B‐075‐020; Taipei Veterans General Hospital, Grant/Award Number: V110C‐054
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1043-3074
1097-0347
DOI:10.1002/hed.27238